Heart Disease Trial, Recruiting NCT06535568 Sponsor: Fondazione Ricerca e Innovazione Cardiovascolare ETS Condition: Heart Disease
Back to Heart Disease

Heart Disease Trial, Recruiting

NCT06535568
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 75 or older, or people aged 18 or older who have a high risk of bleeding
  • People who have just had a successful procedure (called PCI) using a specific medical device called the Essential Pro DCB, treating 1, 2, or 3 heart arteries
  • People with stable or unstable heart artery conditions
  • People whose treated artery blockages were in vessels of a certain size (between 2.0 and 4.0 mm wide, as estimated visually)
  • People who have given their own informed consent to take part, or whose consent was witnessed by an impartial person

Who may not be able to join:

  • People who had a stent placed either during this procedure or in the past 6 months
  • People with a known allergy or medical reason to avoid aspirin, heparin, clopidogrel, paclitaxel, or contrast dye that cannot be managed with pre-treatment medication
  • People who are pregnant at the time of hospitalisation
  • People currently taking part in another clinical trial involving an investigational drug or device within the past 30 days (or within a specified timeframe related to that drug)
  • People who have had a type of serious heart attack called an ST-elevation myocardial infarction (STEMI)
  • People with a life expectancy of less than 12 months
  • People whose heart pumping function is severely reduced (below 30%)
  • People who have a blood clot visible at the site of the artery being treated
  • People whose treated artery has certain complex characteristics, such as: severe calcium build-up in the artery walls, a blockage in the main left heart artery, a fully blocked artery requiring a complex approach, or a blockage located in a bypass graft (confirm with trial site)
  • People with a history of asthma triggered by aspirin or similar anti-inflammatory medicines (NSAIDs)
  • People with a history of stomach or intestinal perforation, ulcers, or bleeding related to NSAIDs or blood-thinning medications, or a history of bleeding in the brain
  • People with current active stomach ulcers
  • People with bleeding disorders or ongoing active bleeding
  • People with severely reduced kidney function
  • People with severely reduced liver function, including abnormal liver test results
  • People with severe heart failure (classified as NYHA grade III or IV)
  • People taking a medication called methotrexate at doses of 15 mg per week or more
  • People with a low white blood cell count at the start of the trial
  • People who are breastfeeding
  • People with a severe overactive thyroid condition
  • People considered to have a very high risk of blood clots

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 216-296-9747

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Fondazione Ricerca e Innovazione Cardiovascolare ETS
Registry
ClinicalTrials.gov
Start date
10 January 2026
Est. completion
20 January 2028

Where this trial is recruiting

🇮🇹 Italy

Primary endpoints

Rate of Net Adverse Clinical Events (NACE) at 12 months

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov